why choose us

First received: September 04, 2022

Clinical Trial: Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children

Study Status: Completed

Recruit Status: RECRUITING

Condition: Vaccine Reaction

Study Type: INTERVENTIONAL


Official Title: A Phase III, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children Aged 12-17 Years in Indonesia

Brief Summary: A Phase III, Observer-blind, randomized, active-controlled prospective intervention study

Read more